Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

PKPaul KollerDYDongyun YangIAIbrahim Aldoss

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds intensive chemotherapy followed by allogeneic transplant improves progression-free survival in patients with acute myeloid leukemia, suggesting better treatment strategies

Key Points

  • Overall survival and progression-free survival improved with intensive chemotherapy bridging to transplant, supporting a promising treatment option.
  • The study observed a median overall survival of 12.7 months and progression-free survival of 8.1 months post-transplant.
  • Retrospective analysis included adult patients who received intensive chemotherapy followed by allogeneic hematopoietic cell transplant.
  • Findings indicate a need for future strategies to enhance disease control and manage complications, such as graft-versus-host disease.

Cite This Study

Koller et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da66https://doi.org/10.1182/blood-2025-3411
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality2025
  2. 2Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation2025
  3. 3Conditioning intensity and post-transplant outcomes in acute myeloid leukemia: A real-world analysis.2026
  4. 4Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial2025
  5. 5Long-term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors2025